UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Biotherapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 83-1863385 (State or other ju ...

Exhibit 99.1 Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, MA – August 5, 2025– Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter 2025, and pro ...

- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter 2025, and provided a corporate update. “The second quarter was a key inflection point for Sensei, as we now tran ...

Core Insights - The broader stock market experienced significant losses due to trade policy changes and negative economic data, while select health technology stocks, including 4D Molecular Therapeutics, Sensei Biotherapeutics, and Alphatec Holdings, saw substantial gains averaging around 37% [1] Group 1: 4D Molecular Therapeutics - Shares of 4D Molecular Therapeutics surged over 42% to close at $6.42 following the release of promising clinical data for its gene therapy candidate, 4D-150, targeting diabetic macular edema and wet age-related macular degeneration [2] - The therapy showed strong, dose-dependent results, with a reported 78% reduction in treatment burden at the Phase 3 dose compared to standard aflibercept dosing, along with sustained visual improvements and no reported inflammation [4] - The European Medicines Agency endorsed the company's plan to seek approval based on a single Phase 3 trial, aligning with earlier FDA guidance [5] Group 2: Sensei Biotherapeutics - Sensei Biotherapeutics emerged as a top gainer despite no major company-specific news, likely due to increased speculative interest in its immuno-oncology pipeline and anticipation of upcoming trial data [6] - The stock rose 38% to close at $10.32, following the announcement that Sensei will present clinical data from its Phase 1/2 trial of its lead candidate at the European Society for Medical Oncology Congress on October 17 [7] Group 3: Alphatec Holdings - Alphatec Holdings' stock jumped 30% to close at $13.77 after the company raised its full-year 2025 revenue outlook to $742 million, driven by strong demand for its surgical platforms and EOS imaging technologies [9] - The company reported second-quarter 2025 revenue of $185.5 million, reflecting a 28% year-over-year increase, although it also reported a widened net loss of $41.1 million, or $0.27 per share [11] - Despite remaining unprofitable, investor confidence appears to be increasing in Alphatec's commercial execution and long-term growth prospects [12]

BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug alone and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, will be presented in a mini oral session at the European Society for Medical Oncology (ESMO) Congress 20 ...

Core Viewpoint - Sensei Biotherapeutics, Inc. is implementing a 1-for-20 reverse stock split to comply with Nasdaq Capital Market's minimum bid price requirement, effective June 16, 2025 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of issued and outstanding shares from approximately 25.2 million to about 1.3 million [3]. - The authorized shares will decrease from 250 million to 12.5 million [3]. - Fractional shares will not be issued; instead, stockholders entitled to fractional shares will receive a cash payment [4]. Group 2: Trading Information - The common stock will begin trading on a split-adjusted basis on June 17, 2025, under the existing trading symbol "SNSE" [2]. - Equiniti Trust Company, LLC will act as the exchange agent and transfer agent for the reverse stock split [5]. Group 3: Company Overview - Sensei Biotherapeutics focuses on developing next-generation therapeutics for cancer patients through its TMAb™ platform [6]. - The lead product candidate, solnerstotug, is designed to block the VISTA checkpoint selectively within the tumor microenvironment [6].

PART I FINANCIAL INFORMATION Presents the company's unaudited financial statements, management's analysis, and disclosures on market risk and internal controls [Item 1. Condensed Consolidated Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20%28Unaudited%29) The unaudited financial statements for Q1 2025 show a net loss of **$6.9 million**, a decrease in total assets to **$38.3 million**, and an accumulated deficit of **$268.9 million**, raising substantial doubt about going concern [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $9,877 | $9,994 | | Marketable securities | $24,454 | $31,341 | | Total current assets | $35,682 | $41,929 | | **Total assets** | **$38,273** | **$45,361** | | **Liabilities & Equity** | | | | Total current liabilities | $5,229 | $5,448 | | **Total liabilities** | **$6,286** | **$6,975** | | **Total stockholders' equity** | **$31,987** | **$38,386** | | Accumulated deficit | $(268,916) | $(262,052) | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Statement of Operations Highlights (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Research and development | $3,725 | $4,917 | | General and administrative | $3,549 | $3,813 | | **Total operating expenses** | **$7,274** | **$8,730** | | Loss from operations | $(7,274) | $(8,730) | | **Net loss** | **$(6,864)** | **$(7,992)** | | Net loss per common share | $(0.27) | $(0.32) | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary (in thousands) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(7,094) | $(7,616) | | Net cash provided by investing activities | $7,191 | $5,770 | | Net cash used in financing activities | $(214) | $(209) | | **Net decrease in cash and cash equivalents** | **$(117)** | **$(2,055)** | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) - The company is a clinical-stage biotechnology firm focused on cancer therapeutics, but has incurred substantial losses, with an accumulated deficit of **$268.9 million** as of March 31, 2025[21](index=21&type=chunk)[22](index=22&type=chunk) - Management has concluded there is substantial doubt about the company's ability to continue as a going concern, as available cash is not sufficient to fund operations for more than **one year** without additional financing[23](index=23&type=chunk)[24](index=24&type=chunk) - In November 2024, the company initiated a restructuring to focus resources on the clinical development of its lead candidate, solnerstotug. This involved closing its Rockville, MD research site and reducing its workforce by approximately **46%**[71](index=71&type=chunk) Stock-Based Compensation Expense (in thousands) | Category | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Research and development | $126 | $339 | | General and administrative | $335 | $877 | | **Total** | **$461** | **$1,216** | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's strategic shift to focus on solnerstotug, resulting in reduced operating expenses and a cash runway into Q2 2026, while reiterating substantial doubt about its going concern ability [Overview](index=24&type=section&id=MD%26A%20-%20Overview) - The company is a clinical-stage biotechnology company focused on its TMAb™ (Tumor Microenvironment Activated Biologics) platform to develop therapeutics for cancer patients[75](index=75&type=chunk) - The lead product candidate, solnerstotug, is in a Phase 1/2 clinical trial for advanced solid tumors. Enrollment in the Phase 1 portion is complete, with updated data expected by the end of 2025[76](index=76&type=chunk) - A November 2024 restructuring paused development of preclinical candidates (SNS-102, SNS-103, SNS-201) and reduced the workforce by **46%** to focus resources on solnerstotug[77](index=77&type=chunk) [Results of Operations](index=28&type=section&id=MD%26A%20-%20Results%20of%20Operations) Comparison of Operations (in thousands) | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Research and development | $3,725 | $4,917 | $(1,192) | | General and administrative | $3,549 | $3,813 | $(264) | | **Total operating expenses** | **$7,274** | **$8,730** | **$(1,456)** | | **Net loss** | **$(6,864)** | **$(7,992)** | **$1,128** | - The **$1.2 million** decrease in R&D expenses was primarily due to lower personnel costs (**$0.8M**), facilities/equipment costs (**$0.4M**), and lab supply purchases (**$0.3M**), partially offset by a **$0.7M** increase in clinical trial expenses[95](index=95&type=chunk) - The **$0.3 million** decrease in G&A expenses was mainly attributable to lower personnel costs (**$0.6M**), partially offset by higher consulting and administrative fees[96](index=96&type=chunk) [Liquidity and Capital Resources](index=28&type=section&id=MD%26A%20-%20Liquidity%20and%20Capital%20Resources) - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities of **$34.3 million** and an accumulated deficit of **$268.9 million**[99](index=99&type=chunk) - The company expects its current cash to fund operating expenses and capital requirements into the second quarter of 2026[112](index=112&type=chunk) - There is substantial doubt about the company's ability to continue as a going concern beyond **one year** from the financial statement issuance date, and additional financing is required to support operations[112](index=112&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=37&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, the company is exempt from providing quantitative and qualitative disclosures about market risk - Sensei Biotherapeutics is a smaller reporting company as defined by Item 10 of Regulation S-K and is not required to provide quantitative and qualitative disclosures about market risk[127](index=127&type=chunk) [Item 4. Controls and Procedures](index=37&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes in internal control over financial reporting during the quarter - Management concluded that the company's disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2025[130](index=130&type=chunk) - There were no material changes in internal control over financial reporting during the three months ended March 31, 2025[131](index=131&type=chunk) PART II OTHER INFORMATION Presents other required information including legal proceedings, risk factors, equity sales, and exhibits [Item 1. Legal Proceedings](index=38&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings - The company is not currently a party to any material legal proceedings[134](index=134&type=chunk) [Item 1A. Risk Factors](index=38&type=section&id=Item%201A.%20Risk%20Factors) This section details significant risks including financial viability, dependence on solnerstotug, reliance on third parties, regulatory hurdles, commercialization challenges, intellectual property, and operational risks [Risks Related to our Financial Position](index=40&type=section&id=Risks%20Related%20to%20our%20Financial%20Position) - The company will need substantial additional funding to complete the development of its product candidates and a failure to obtain this capital could force it to delay, limit, or terminate its efforts[141](index=141&type=chunk) - The company has a history of significant losses, an accumulated deficit of **$268.9 million** as of March 31, 2025, and may never achieve profitability[153](index=153&type=chunk) - There is substantial doubt about the company's ability to continue as a going concern, as current cash is only expected to fund operations into the second quarter of 2026[161](index=161&type=chunk) [Risks Related to the Development of our Product Candidates](index=46&type=section&id=Risks%20Related%20to%20the%20Development%20of%20our%20Product%20Candidates) - The company's development efforts are in early stages, and its business is highly dependent on the success of its one clinical candidate, solnerstotug[167](index=167&type=chunk)[181](index=181&type=chunk) - The therapeutic efficacy of solnerstotug is unproven in humans, and there are no currently approved therapies targeting its VISTA checkpoint, making development inherently risky[170](index=170&type=chunk) - Clinical trials are difficult, expensive, and have uncertain outcomes. Interim data may change, and failure to demonstrate safety and efficacy could halt development[187](index=187&type=chunk)[190](index=190&type=chunk)[193](index=193&type=chunk) [Risks Related to Manufacturing and our Dependence on Third Parties](index=61&type=section&id=Risks%20Related%20to%20Manufacturing%20and%20our%20Dependence%20on%20Third%20Parties) - The company relies on third-party CROs to conduct clinical trials and on CMOs for the production of solnerstotug, which increases risks related to performance, quality, cost, and supply[213](index=213&type=chunk)[227](index=227&type=chunk) - The clinical trial for solnerstotug is being evaluated in combination with cemiplimab, and the company depends on a supply agreement with Regeneron for this third-party drug[223](index=223&type=chunk) [Risks Related to Regulatory Approval and Legal Compliance](index=71&type=section&id=Risks%20Related%20to%20Regulatory%20Approval%20and%20Legal%20Compliance) - The company must obtain regulatory approval from the FDA and other authorities, a lengthy and uncertain process, before commercializing any product candidates[245](index=245&type=chunk) - Even if approved, the company will be subject to ongoing regulatory obligations, and any approved products could be subject to marketing restrictions, recalls, or withdrawal if safety issues arise[252](index=252&type=chunk) - Healthcare legislative reform, such as the Inflation Reduction Act (IRA), could adversely affect the business by impacting drug pricing, reimbursement, and profitability[263](index=263&type=chunk)[264](index=264&type=chunk)[266](index=266&type=chunk) [Risks Related to the Commercialization of our Product Candidates](index=83&type=section&id=Risks%20Related%20to%20the%20Commercialization%20of%20our%20Product%20Candidates) - The company currently has no sales, marketing, or distribution capabilities and will need to build them or partner with third parties to commercialize any approved products[279](index=279&type=chunk) - The biopharmaceutical industry is highly competitive, and the company faces competition from major pharmaceutical companies with greater resources[282](index=282&type=chunk)[285](index=285&type=chunk) - Commercial success depends on market acceptance by physicians and patients, as well as securing adequate coverage and reimbursement from government and private payors[289](index=289&type=chunk)[293](index=293&type=chunk) [Risks Related to Our Intellectual Property](index=89&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) - The company's success depends on its ability to obtain and maintain patent protection for its technology and product candidates, which is an uncertain and expensive process[306](index=306&type=chunk) - The company may face lawsuits from third parties alleging infringement of their intellectual property rights, which could be costly and force a halt to commercialization[315](index=315&type=chunk) - The company relies on trade secrets and confidentiality agreements, which may be breached or may not provide adequate protection against competitors[330](index=330&type=chunk) [Risks Related to our Business Operations](index=99&type=section&id=Risks%20Related%20to%20our%20Business%20Operations) - The company's success depends on its ability to attract and retain key management and qualified scientific personnel in a highly competitive industry[339](index=339&type=chunk) - The November 2024 workforce reduction may have unintended consequences, including loss of institutional knowledge, decreased morale, and failure to achieve anticipated benefits[342](index=342&type=chunk) [Risks Related to our Securities and our Status as a Public Company](index=101&type=section&id=Risks%20Related%20to%20our%20Securities%20and%20our%20Status%20as%20a%20Public%20Company) - The company's stock price is likely to be highly volatile, and it has received a notice from Nasdaq for failing to meet the minimum **$1.00** bid price requirement[348](index=348&type=chunk)[354](index=354&type=chunk) - The company is an "emerging growth company" and a "smaller reporting company," which allows for reduced disclosure requirements that may make its stock less attractive to some investors[365](index=365&type=chunk) - Insiders own over **30%** of the company's common stock, giving them substantial influence over stockholder matters[379](index=379&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=116&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) There were no unregistered sales of equity securities during the quarter, and the use of IPO proceeds section is not applicable - There were no recent sales of unregistered equity securities during the reported period[404](index=404&type=chunk) [Item 3. Defaults Upon Senior Securities](index=118&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - None[407](index=407&type=chunk) [Item 4. Mine Safety Disclosures](index=118&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[408](index=408&type=chunk) [Item 5. Other Information](index=118&type=section&id=Item%205.%20Other%20Information) No officers or directors adopted, modified, or terminated Rule 10b5-1 trading arrangements during the quarter - During the quarter ended March 31, 2025, no officers or directors adopted, modified, or terminated a Rule 10b5-1 trading plan[409](index=409&type=chunk) [Item 6. Exhibits](index=118&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the report, including corporate documents and required Sarbanes-Oxley certifications - The exhibits filed with this report include certifications from the Principal Executive Officer and Principal Financial Officer as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002[410](index=410&type=chunk)

[Report Highlights and Corporate Updates](index=1&type=section&id=Report%20Highlights%20and%20Corporate%20Updates) Sensei Biotherapeutics announced a successful first quarter of 2025, highlighted by favorable clinical data for its lead candidate, solnerstotug, in difficult-to-treat PD-(L)1 resistant cancer patients. The company completed enrollment for its dose expansion study and confirmed a cash runway sufficient to fund operations into the second quarter of 2026 - Observed favorable signs of clinical activity in patients with PD-(L)1-resistant cancers, with response rates nearly **three times higher** than typically expected[1](index=1&type=chunk)[3](index=3&type=chunk) - Dose expansion enrollment is now complete, with the full dataset anticipated to be presented by the **end of 2025**[1](index=1&type=chunk)[7](index=7&type=chunk) - The company projects its current cash, cash equivalents, and marketable securities will fund operations into the **second quarter of 2026**[1](index=1&type=chunk)[8](index=8&type=chunk) [Clinical Program Update: Solnerstotug (SNS-101)](index=1&type=section&id=Clinical%20Program%20Update%3A%20Solnerstotug%20%28SNS-101%29) The Phase 1/2 clinical trial for solnerstotug, a conditionally active antibody targeting the VISTA immune checkpoint, has completed its dose expansion enrollment. The trial is evaluating the drug as both a monotherapy and in combination with Libtayo® in patients with advanced solid tumors, with a focus on PD-(L)1 resistant cases - Solnerstotug is a conditionally active antibody designed to selectively target the VISTA immune checkpoint within the tumor microenvironment[4](index=4&type=chunk) - A Phase 1/2 clinical trial is evaluating solnerstotug's safety and efficacy as a monotherapy and in combination with Regeneron's PD-1 inhibitor Libtayo® (cemiplimab)[5](index=5&type=chunk) Dose Expansion Enrollment Completion (Total 63 Patients) | Arm | Patient Group | Number of Patients | | :--- | :--- | :--- | | **Monotherapy** | MSS CRC | 10 | | **Combination (w/ cemiplimab)** | MSS CRC | 10 | | | PD-(L)1 resistant "hot" tumors | 43 | [First Quarter 2025 Financial Results](index=2&type=section&id=First%20Quarter%202025%20Financial%20Results) For the first quarter of 2025, Sensei reported a net loss of $6.9 million, a decrease from $8.0 million in the prior-year period. The company's cash position remains strong at $34.3 million. Both R&D and G&A expenses saw year-over-year reductions, primarily due to lower personnel costs Cash Position as of March 31, 2025 | Category | Amount (in millions) | | :--- | :--- | | Cash, cash equivalents and marketable securities | $34.3 | | *Comparison to Dec 31, 2024* | *$41.3* | Quarterly Expense Comparison (Q1 2025 vs Q1 2024) | Expense Category | Q1 2025 (in millions) | Q1 2024 (in millions) | Change | | :--- | :--- | :--- | :--- | | R&D Expenses | $3.7 | $4.9 | Decrease | | G&A Expenses | $3.5 | $3.8 | Decrease | Net Loss Comparison (Q1 2025 vs Q1 2024) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Loss | $6.9 million | $8.0 million | | Net Loss Per Share | $0.27 | $0.32 | [Condensed Statements of Operations](index=3&type=section&id=Condensed%20Statements%20of%20Operations) For the three months ended March 31, 2025, total operating expenses were $7.3 million, down from $8.7 million in the same period of 2024. This led to a reduced net loss of $6.9 million ($0.27 per share) compared to a net loss of $8.0 million ($0.32 per share) in Q1 2024 Statement of Operations (Unaudited, in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | **Total operating expenses** | $7,274 | $8,730 | | **Loss from operations** | $(7,274) | $(8,730) | | **Net loss** | $(6,864) | $(7,992) | | **Net loss per share, basic and diluted** | $(0.27) | $(0.32) | [Selected Condensed Balance Sheet Data](index=3&type=section&id=Selected%20Condensed%20Balance%20Sheet%20Data) As of March 31, 2025, the company held $34.3 million in cash, cash equivalents, and marketable securities. Total assets stood at $38.3 million, with total stockholders' equity at $32.0 million Balance Sheet Data (Unaudited, in thousands) | | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $9,877 | $9,994 | | **Marketable securities** | $24,454 | $31,341 | | **Total assets** | $38,273 | $45,361 | | **Total stockholders' equity** | $31,987 | $38,386 | [Corporate Activities](index=2&type=section&id=Corporate%20Activities) During the first quarter of 2025, CEO John Celebi represented Sensei Biotherapeutics at two key industry conferences, presenting the company's clinical progress and strategic direction to the investment community - Participated in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference on **April 7, 2025**[13](index=13&type=chunk) - Delivered a presentation at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on **February 11, 2025**[13](index=13&type=chunk) [Cautionary Note Regarding Forward-Looking Statements](index=3&type=section&id=Cautionary%20Note%20Regarding%20Forward-Looking%20Statements) The report includes forward-looking statements concerning the potential benefits of its product candidates, clinical trial timelines, and its financial runway. It cautions that these are subject to significant risks and uncertainties, including clinical development failures, trial delays, and reliance on third-party suppliers, which could cause actual results to differ - Statements regarding the development, therapeutic benefits, clinical trial timing, and financial sufficiency (cash runway) are forward-looking[18](index=18&type=chunk) - Key risks include unsuccessful commercialization, trial delays or cessations, non-replication of prior results, and dependence on third-party suppliers[18](index=18&type=chunk)[19](index=19&type=chunk)

Core Insights - Sensei Biotherapeutics reported favorable clinical data for its lead product candidate, solnerstotug, in patients with PD-(L)1-resistant cancers, indicating a potential breakthrough in treatment options for this challenging patient population [2][3] - The company has completed enrollment for its dose expansion cohort and expects to present full data by the end of 2025 [1][6] - Sensei's cash position is strong, with a runway expected to last into the second quarter of 2026 [5] Clinical Development - Solnerstotug is designed to target the immune checkpoint VISTA, which is associated with poor survival rates in various cancers [3] - The ongoing Phase 1/2 clinical trial is evaluating solnerstotug both as a monotherapy and in combination with Regeneron's PD-1 inhibitor, Libtayo [4] - Preliminary data from the trial shows response rates nearly three times higher than historical expectations for PD-(L)1-resistant patients [2][6] Financial Performance - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $34.3 million, down from $41.3 million at the end of 2024 [5] - Research and Development (R&D) expenses decreased to $3.7 million in Q1 2025 from $4.9 million in Q1 2024, primarily due to lower personnel and facility costs [7] - General and Administrative (G&A) expenses also saw a decrease, totaling $3.5 million in Q1 2025 compared to $3.8 million in Q1 2024 [8] Operational Highlights - The company has completed enrollment of 63 patients in the dose expansion stage, including 10 patients with microsatellite stable colorectal cancer (MSS CRC) and 53 patients with PD-(L)1-resistant "hot" tumors [6] - Sensei participated in various conferences to discuss its clinical progress and strategic direction, enhancing its visibility in the oncology sector [6]

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET. About Sensei Biotherapeutics Sensei Bi ...